Payment overview · 2025
General Payments
$184.38
10 reported records · 5 companies
Healthcare provider profile · identity verified
Thomas Craig Darter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHILDRESS, TX · NPI 1467553370
Verified facts
What the public records show
CMS Open Payments records show Thomas Craig Darter, M.D. received $184.38 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.50 | 46.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.31 | 21.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.79 | 12.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.46 | 9.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.32 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.38 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.50 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.03 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 730 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 87 |
| Gabapentin | Gabapentin | 565 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 100 |
| Omeprazole | Omeprazole | 449 | 94 |
| Furosemide | Furosemide | 444 | 79 |
| Potassium Chloride | Potassium Chloride | 389 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 357 | 55 |
| Mirtazapine | Mirtazapine | 336 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 54 |
| Lisinopril | Lisinopril | 322 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 56 |
| Metformin Hcl | Metformin Hcl | 281 | 59 |
| Meloxicam | Meloxicam | 271 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 43 |
| Eliquis | Apixaban | 236 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 31 |
| Buspirone Hcl | Buspirone Hcl | 207 | 36 |
| Celecoxib | Celecoxib | 194 | 38 |
| Losartan Potassium | Losartan Potassium | 193 | 27 |
| Sertraline Hcl | Sertraline Hcl | 193 | 23 |
| Tramadol Hcl | Tramadol Hcl | 189 | 51 |
| Simvastatin | Simvastatin | 185 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 31 |
| Carvedilol | Carvedilol | 177 | 32 |
| Methocarbamol | Methocarbamol | 163 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 155 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 154 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 27 |
| Glimepiride | Glimepiride | 149 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 25 |
| Ozempic | Semaglutide | 136 | 19 |
| Alprazolam | Alprazolam | 135 | 18 |
| Allopurinol | Allopurinol | 134 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 26 |
| Prednisone | Prednisone | 124 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 106 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 66 |
| Donepezil Hcl | Donepezil Hcl | 96 | 14 |
| Clonazepam | Clonazepam | 89 | 12 |
| Mounjaro | Tirzepatide | 89 | suppressed |
| Ondansetron Odt | Ondansetron | 89 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 18 |
| Memantine Hcl | Memantine Hcl | 82 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 12 |
| Jardiance | Empagliflozin | 78 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 17 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 55 |
| Naproxen | Naproxen | 68 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 68 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 12 |
| Estradiol | Estradiol | 65 | 13 |
| Montelukast Sodium | Montelukast Sodium | 65 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 11 |
| Clonidine Hcl | Clonidine Hcl | 62 | suppressed |
| Metolazone | Metolazone | 62 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 12 |
| Divalproex Sodium | Divalproex Sodium | 56 | suppressed |
| Glipizide | Glipizide | 56 | suppressed |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Azithromycin | Azithromycin | 54 | 45 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 52 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 11 |
| Ibuprofen | Ibuprofen | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Finasteride | Finasteride | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 13 |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 18 |
| Valsartan | Valsartan | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 25 |
| Nystatin | Nystatin | 38 | 18 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Nitroglycerin | Nitroglycerin | 30 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 18 |
| Fluconazole | Fluconazole | 28 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.38 · 10 records | Novo Nordisk Inc | AIRSUPRA, ELIQUIS, LEQVIO, NUZYRA, Ozempic, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error